Monitoring outcomes of new disease modifying interventions and optimization of risk assessment in Alzheimer's disease

Go Back to All Clinical Trials

Monitoring outcomes of new disease modifying interventions and optimization of risk assessment in Alzheimer's disease

Brief description of study

The purpose of this study is to develop an easier way to predict brain changes that might occur from Alzheimer's treatments, especially those using antibody therapies like Leqembi (Lecanemab).

These therapies can occasionally cause brain changes, like swelling or small internal bleeding, which are usually harmless but sometimes can cause symptoms like headaches or confusion. Normally, these changes are monitored with MRI scans. However, we want to see if a simple blood test could serve as a more convenient alternative to MRIs.

Clinical Study Identifier: s23-01483

Principal Investigator: Thomas M Wisniewski.

Other Investigators: Ludovic Debure, Anaztasia Ulysse, Arjun V. Masurkar, Karyn D Marsh, Ricardo Miguel Osorio Suarez, Allal Boutajangout, Timothy Michael Shepherd, Alison C Pietras, Alok Vedvyas.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies